Table 2 Patient characteristics
Factors | N | % |
|---|---|---|
Total | 439 | 100 |
Age (years old) | ||
Median (range) | 73 (33–92) | |
Quartile | 68 and 78 | |
iPSA (ng/mL) | ||
Median (range) | 9.2 (1.6–24.0) | |
Quartile | 6.3 and 14.7 | |
Clinical T-stage | ||
T1c | 84 | 19.1 |
T2a | 208 | 47.4 |
T2b | 20 | 4.6 |
T2c | 61 | 13.9 |
T3a | 46 | 10.5 |
T3b | 14 | 3.2 |
T4 | 6 | 1.4 |
Gleason score group | ||
Group 1 | 46 | 10.5 |
Group 2 | 121 | 27.6 |
Group 3 | 117 | 26.7 |
Group 4 | 82 | 18.7 |
Group 5 | 73 | 16.6 |
Risk group | ||
Low | 21 | 4.8 |
Intermediate-low | 84 | 19.1 |
Intermediate-high | 149 | 33.9 |
High | 112 | 25.5 |
Ver-high | 73 | 16.6 |
Hormonal therapy | ||
None | 98 | 22.3 |
Short term | 183 | 41.7 |
Long term | 158 | 36.0 |
RT total dose | ||
36.25 Gy | 239 | 54.4 |
40 Gy | 187 | 42.6 |
42.5 Gy | 13 | 3.0 |